-
Something wrong with this record ?
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
G. Bisogno, GL. De Salvo, C. Bergeron, S. Gallego Melcón, JH. Merks, A. Kelsey, H. Martelli, V. Minard-Colin, D. Orbach, H. Glosli, J. Chisholm, M. Casanova, I. Zanetti, C. Devalck, M. Ben-Arush, P. Mudry, S. Ferman, M. Jenney, A. Ferrari,...
Language English Country Great Britain
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Rhabdomyosarcoma, Alveolar drug therapy mortality pathology MeSH
- Time Factors MeSH
- Cyclophosphamide administration & dosage adverse effects MeSH
- Child MeSH
- Rhabdomyosarcoma, Embryonal drug therapy mortality pathology MeSH
- Risk Assessment MeSH
- Remission Induction MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Disease-Free Survival MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage adverse effects MeSH
- Risk Factors MeSH
- Maintenance Chemotherapy * adverse effects mortality MeSH
- Vinorelbine administration & dosage adverse effects MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Geographicals
- Argentina MeSH
- Brazil MeSH
- Europe MeSH
- Israel MeSH
BACKGROUND: For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival in patients with high-risk rhabdomyosarcoma. METHODS: RMS 2005 was a multicentre, open-label, randomised, controlled, phase 3 trial done at 102 hospitals in 14 countries. We included patients aged 6 months to 21 years with rhabdomyosarcoma who were considered to be at high risk of relapse: those with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring at unfavourable sites with unfavourable age (≥10 years) or tumour size (>5 cm), or both; those with any non-metastatic rhabdomyosarcoma with nodal involvement; and those with non-metastatic alveolar rhabdomyosarcoma but without nodal involvement. Patients in remission after standard treatment (nine cycles of ifosfamide, vincristine, dactinomycin with or without doxorubicin, and surgery or radiotherapy, or both) were randomly assigned (1:1) to stop treatment or continue maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2, on days 1-28). Randomisation was done by use of a web-based system and was stratified (block size of four) by enrolling country and risk subgroup. Neither investigators nor patients were masked to treatment allocation. The primary outcome was disease-free survival in the intention-to-treat population. Secondary outcomes were overall survival and toxicity. This trial is registered with EudraCT, number 2005-000217-35, and ClinicalTrials.gov, number NCT00339118, and follow-up is ongoing. FINDINGS: Between April 20, 2006, and Dec 21, 2016, 371 patients were enrolled and randomly assigned to the two groups: 186 to stop treatment and 185 to receive maintenance chemotherapy. Median follow-up was 60·3 months (IQR 32·4-89·4). In the intention-to-treat population, 5-year disease-free survival was 77·6% (95% CI 70·6-83·2) with maintenance chemotherapy versus 69·8% (62·2-76·2) without maintenance chemotherapy (hazard ratio [HR] 0·68 [95% CI 0·45-1·02]; p=0·061), and 5-year overall survival was 86·5% (95% CI 80·2-90·9) with maintenance chemotherapy versus 73·7% (65·8-80·1) without (HR 0·52 [95% CI 0·32-0·86]; p=0·0097). Toxicity was manageable in patients who received maintenance chemotherapy: 136 (75%) of 181 patients had grade 3-4 leucopenia, 148 (82%) had grade 3-4 neutropenia, 19 (10%) had anaemia, two (1%) had thrombocytopenia, and 56 (31%) had an infection. One (1%) patient had a grade 4 non-haematological toxicity (neurotoxicity). Two treatment-related serious adverse events occurred: one case of inappropriate antidiuretic hormone secretion and one of a severe steppage gait with limb pain, both of which resolved. INTERPRETATION: Adding maintenance chemotherapy seems to improve survival for patients with high-risk rhabdomyosarcoma. This approach will be the new standard of care for patients with high-risk rhabdomyosarcoma in future EpSSG trials. FUNDING: Fondazione Città della Speranza, Association Léon Berard Enfant Cancéreux, Clinical Research Hospital Program (French Ministry of Health), and Cancer Research UK.
Children and Young Peoples Unit Royal Marsden Hospital Sutton Surrey UK
Clinical Research Unit Istituto Oncologico Veneto IOV IRCCS Padova Italy
Department of Paediatric and Adolescent Oncology Gustave Roussy Villejuif France
Department of Paediatric Histopathology Royal Manchester Children's Hospital Manchester UK
Department of Paediatric Oncology Children's Hospital for Wales Heath Park Cardiff UK
Institut d'Hématologie et d'Oncologie Pédiatrique Centre Léon Bérard Lyon France
Instituto Nacional de Câncer Rio de Janeiro Brazil
Paediatric Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Princess Máxima Center for Paediatric Oncology Utrecht Netherlands
Servicio de Oncología y Hematología Pediatrica Hospital Universitari Vall d'Hebron Barcelona Spain
SIREDO Oncology Center Institut Curie PSL University Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025547
- 003
- CZ-PrNML
- 005
- 20201222153946.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(19)30617-5 $2 doi
- 035 __
- $a (PubMed)31562043
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Bisogno, Gianni $u Haematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy. Electronic address: gianni.bisogno@unipd.it.
- 245 10
- $a Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial / $c G. Bisogno, GL. De Salvo, C. Bergeron, S. Gallego Melcón, JH. Merks, A. Kelsey, H. Martelli, V. Minard-Colin, D. Orbach, H. Glosli, J. Chisholm, M. Casanova, I. Zanetti, C. Devalck, M. Ben-Arush, P. Mudry, S. Ferman, M. Jenney, A. Ferrari, European paediatric Soft tissue sarcoma Study Group,
- 520 9_
- $a BACKGROUND: For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival in patients with high-risk rhabdomyosarcoma. METHODS: RMS 2005 was a multicentre, open-label, randomised, controlled, phase 3 trial done at 102 hospitals in 14 countries. We included patients aged 6 months to 21 years with rhabdomyosarcoma who were considered to be at high risk of relapse: those with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring at unfavourable sites with unfavourable age (≥10 years) or tumour size (>5 cm), or both; those with any non-metastatic rhabdomyosarcoma with nodal involvement; and those with non-metastatic alveolar rhabdomyosarcoma but without nodal involvement. Patients in remission after standard treatment (nine cycles of ifosfamide, vincristine, dactinomycin with or without doxorubicin, and surgery or radiotherapy, or both) were randomly assigned (1:1) to stop treatment or continue maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2, on days 1-28). Randomisation was done by use of a web-based system and was stratified (block size of four) by enrolling country and risk subgroup. Neither investigators nor patients were masked to treatment allocation. The primary outcome was disease-free survival in the intention-to-treat population. Secondary outcomes were overall survival and toxicity. This trial is registered with EudraCT, number 2005-000217-35, and ClinicalTrials.gov, number NCT00339118, and follow-up is ongoing. FINDINGS: Between April 20, 2006, and Dec 21, 2016, 371 patients were enrolled and randomly assigned to the two groups: 186 to stop treatment and 185 to receive maintenance chemotherapy. Median follow-up was 60·3 months (IQR 32·4-89·4). In the intention-to-treat population, 5-year disease-free survival was 77·6% (95% CI 70·6-83·2) with maintenance chemotherapy versus 69·8% (62·2-76·2) without maintenance chemotherapy (hazard ratio [HR] 0·68 [95% CI 0·45-1·02]; p=0·061), and 5-year overall survival was 86·5% (95% CI 80·2-90·9) with maintenance chemotherapy versus 73·7% (65·8-80·1) without (HR 0·52 [95% CI 0·32-0·86]; p=0·0097). Toxicity was manageable in patients who received maintenance chemotherapy: 136 (75%) of 181 patients had grade 3-4 leucopenia, 148 (82%) had grade 3-4 neutropenia, 19 (10%) had anaemia, two (1%) had thrombocytopenia, and 56 (31%) had an infection. One (1%) patient had a grade 4 non-haematological toxicity (neurotoxicity). Two treatment-related serious adverse events occurred: one case of inappropriate antidiuretic hormone secretion and one of a severe steppage gait with limb pain, both of which resolved. INTERPRETATION: Adding maintenance chemotherapy seems to improve survival for patients with high-risk rhabdomyosarcoma. This approach will be the new standard of care for patients with high-risk rhabdomyosarcoma in future EpSSG trials. FUNDING: Fondazione Città della Speranza, Association Léon Berard Enfant Cancéreux, Clinical Research Hospital Program (French Ministry of Health), and Cancer Research UK.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a udržovací chemoterapie $x škodlivé účinky $x mortalita $7 D060046
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a alveolární rhabdomyosarkom $x farmakoterapie $x mortalita $x patologie $7 D018232
- 650 _2
- $a embryonální rhabdomyosarkom $x farmakoterapie $x mortalita $x patologie $7 D018233
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a vinorelbin $x aplikace a dávkování $x škodlivé účinky $7 D000077235
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Argentina $7 D001118
- 651 _2
- $a Brazílie $7 D001938
- 651 _2
- $a Evropa $7 D005060
- 651 _2
- $a Izrael $7 D007557
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a De Salvo, Gian Luca $u Clinical Research Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
- 700 1_
- $a Bergeron, Christophe $u Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France.
- 700 1_
- $a Gallego Melcón, Soledad $u Servicio de Oncología y Hematología Pediatrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Merks, Johannes H $u Princess Máxima Center for Paediatric Oncology, Utrecht, Netherlands; Department of Paediatric Oncology, Emma Children's Hospital-Academic Medical Center Amsterdam, Netherlands.
- 700 1_
- $a Kelsey, Anna $u Department of Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, UK.
- 700 1_
- $a Martelli, Helene $u Department of Paediatric Surgery, Hôpital Bicêtre-Hôpitaux Universitaires Paris Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, Paris, France.
- 700 1_
- $a Minard-Colin, Veronique $u Department of Paediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France.
- 700 1_
- $a Orbach, Daniel $u SIREDO Oncology Center, Institut Curie, PSL University, Paris, France.
- 700 1_
- $a Glosli, Heidi $u Department of Paediatric Research and Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
- 700 1_
- $a Chisholm, Julia $u Children and Young Peoples Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
- 700 1_
- $a Casanova, Michela $u Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Zanetti, Ilaria $u Haematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
- 700 1_
- $a Devalck, Christine $u Paediatric Haematology and Oncology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium.
- 700 1_
- $a Ben-Arush, Myriam $u Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
- 700 1_
- $a Mudry, Peter $u University Children's Hospital Brno, Czech Republic.
- 700 1_
- $a Ferman, Sima $u Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
- 700 1_
- $a Jenney, Meriel $u Department of Paediatric Oncology, Children's Hospital for Wales, Heath Park, Cardiff, UK.
- 700 1_
- $a Ferrari, Andrea $u Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 710 2_
- $a European paediatric Soft tissue sarcoma Study Group
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 20, č. 11 (2019), s. 1566-1575
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31562043 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153942 $b ABA008
- 999 __
- $a ok $b bmc $g 1599692 $s 1116233
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 11 $d 1566-1575 $e 20190924 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20201125
